- Home
- IMAB vs DIAX Comparison
IMAB vs DIAX Comparison
Compare IMAB & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- DIAX
- Stock Information
- Founded
- IMAB 2014
- DIAX 2005
- Country
- IMAB United States
- DIAX United States
- Employees
- IMAB N/A
- DIAX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- IMAB Health Care
- DIAX Finance
- Exchange
- IMAB Nasdaq
- DIAX Nasdaq
- Market Cap
- IMAB 486.4M
- DIAX 535.3M
- IPO Year
- IMAB 2020
- DIAX N/A
- Fundamental
- Price
- IMAB $4.70
- DIAX $14.85
- Analyst Decision
- IMAB Strong Buy
- DIAX
- Analyst Count
- IMAB 6
- DIAX 0
- Target Price
- IMAB $7.50
- DIAX N/A
- AVG Volume (30 Days)
- IMAB 2.2M
- DIAX 96.6K
- Earning Date
- IMAB 11-14-2025
- DIAX 01-01-0001
- Dividend Yield
- IMAB N/A
- DIAX 7.93%
- EPS Growth
- IMAB N/A
- DIAX N/A
- EPS
- IMAB N/A
- DIAX N/A
- Revenue
- IMAB N/A
- DIAX N/A
- Revenue This Year
- IMAB N/A
- DIAX N/A
- Revenue Next Year
- IMAB N/A
- DIAX N/A
- P/E Ratio
- IMAB N/A
- DIAX N/A
- Revenue Growth
- IMAB N/A
- DIAX N/A
- 52 Week Low
- IMAB $0.60
- DIAX $12.80
- 52 Week High
- IMAB $6.79
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- IMAB 49.60
- DIAX 59.19
- Support Level
- IMAB $4.13
- DIAX $14.50
- Resistance Level
- IMAB $6.79
- DIAX $14.79
- Average True Range (ATR)
- IMAB 0.72
- DIAX 0.15
- MACD
- IMAB -0.14
- DIAX 0.02
- Stochastic Oscillator
- IMAB 21.43
- DIAX 81.13
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.